NewAmsterdam Pharma (NASDAQ:NAMS) Position Raised by RA Capital Management L.P.

RA Capital Management L.P. grew its position in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 9.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 8,845,000 shares of the company's stock after acquiring an additional 781,000 shares during the quarter. NewAmsterdam Pharma comprises 3.0% of RA Capital Management L.P.'s holdings, making the stock its 7th largest position. RA Capital Management L.P. owned 9.57% of NewAmsterdam Pharma worth $227,316,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the company. Geode Capital Management LLC raised its holdings in NewAmsterdam Pharma by 1.6% in the 3rd quarter. Geode Capital Management LLC now owns 86,322 shares of the company's stock valued at $1,433,000 after acquiring an additional 1,399 shares during the last quarter. National Bank of Canada FI purchased a new stake in shares of NewAmsterdam Pharma in the fourth quarter valued at approximately $51,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of NewAmsterdam Pharma in the fourth quarter valued at approximately $80,000. Legal & General Group Plc lifted its position in NewAmsterdam Pharma by 24.8% during the fourth quarter. Legal & General Group Plc now owns 22,946 shares of the company's stock worth $590,000 after buying an additional 4,556 shares in the last quarter. Finally, Gilder Gagnon Howe & Co. LLC boosted its stake in NewAmsterdam Pharma by 24.9% during the fourth quarter. Gilder Gagnon Howe & Co. LLC now owns 29,871 shares of the company's stock worth $768,000 after buying an additional 5,949 shares during the last quarter. 89.89% of the stock is owned by institutional investors and hedge funds.

NewAmsterdam Pharma Stock Performance

Shares of NAMS remained flat at $20.03 during trading on Friday. 487,846 shares of the company's stock were exchanged, compared to its average volume of 602,784. The business's fifty day moving average is $19.68 and its 200-day moving average is $21.24. The firm has a market cap of $2.20 billion, a PE ratio of -7.70 and a beta of -0.01. NewAmsterdam Pharma has a 1-year low of $14.06 and a 1-year high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last posted its earnings results on Wednesday, February 26th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.47). The company had revenue of $12.77 million for the quarter, compared to analysts' expectations of $3.30 million. Sell-side analysts predict that NewAmsterdam Pharma will post -1.75 EPS for the current fiscal year.

Insider Activity at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, Director James N. Topper purchased 1,135 shares of the company's stock in a transaction on Wednesday, March 26th. The stock was acquired at an average price of $22.49 per share, for a total transaction of $25,526.15. Following the completion of the purchase, the director now directly owns 3,013,569 shares in the company, valued at approximately $67,775,166.81. The trade was a 0.04 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Louise Frederika Kooij sold 150,000 shares of the company's stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $20.37, for a total value of $3,055,500.00. Following the sale, the chief accounting officer now directly owns 15,000 shares in the company, valued at $305,550. This represents a 90.91 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 19.50% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on NAMS. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $40.00 target price on shares of NewAmsterdam Pharma in a research note on Friday, January 24th. Needham & Company LLC reaffirmed a "buy" rating and set a $42.00 target price on shares of NewAmsterdam Pharma in a research note on Tuesday, April 8th. Scotiabank increased their price target on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the company a "sector outperform" rating in a research note on Thursday, February 27th. HC Wainwright restated a "buy" rating and set a $48.00 price target on shares of NewAmsterdam Pharma in a report on Tuesday, January 14th. Finally, UBS Group set a $41.00 price objective on NewAmsterdam Pharma in a report on Monday, March 3rd. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, NewAmsterdam Pharma presently has a consensus rating of "Buy" and a consensus target price of $43.33.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.